

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 16026442				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		Modified oligonucleotide, nucleobase sequence complementary to a miR-21, microRNA, miR- 21, targets for the diagnosis and/or therapy of fibrosis.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C12N 15/113, A61P 35/00. CPC (Opcional): -		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	CO14238778	28/10/2014	-	-
EPO (25/07/2012)	WO2007027894	08/03/2007	Rv. 1 a 14 (Pág. 32, ejemplo 4).	Y
	WO2009043353	09/04/2009	-	A
	WO2009106367	03/09/2009	Rv. 1 a 14 (Pág. 50, párr. 3 y 4).	Y
	WO2010144485	16/12/2010	-	A
Patbase*	US7582744	01/09/2009	-	A
	US 8017763	13/09/2011	-	A
	US20110071211	24/03/2011	-	A
	US2009326208	31/12/2009	-	A
	WO2011126842	13/10/2011	-	A
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente (ScienceDirect)	-Chan <i>et al.</i> , "MicroRNA-21 is an Antiapoptotic Factor in Human Glioblastoma Cells," Cancer Res., 2005, 65:6029-6033 -Chau <i>et al.</i> , "MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways," Sci Transl Med., 2012, 4:121ra18 -Duffield <i>et al.</i> , "Inhibition of microRNA-21 as a Therapeutic Strategy for Kidney Fibrosis," Abstract SA-OR449, Kidney Week 2011.
---------------------------------------	---

Fecha del reporte de búsqueda:	31/08/2017
--------------------------------	------------

Menu Search History Session Folder Order Help Logoff

Information Shortcuts

- Bibliographic data →
- Textual data →
- Update commands →
- Operators →
- Navigation / shortcuts →

Similar • Translate • Full-text • Status • Citations

PatBase - US20170142603

Saline LNA-anti-miR

100x

Saline treated

LNA-anti-miR treated

Detection probe for: miR-122a

LNA-anti-miR



Figure 10: Fluorescence microscopy images showing the detection of miR-122a in liver tissue. The images are arranged in a 2x2 grid. The top row shows 'Saline' and 'LNA-anti-miR' treatments. The bottom row shows 'Saline treated' and 'LNA-anti-miR treated' conditions. The detection probe for miR-122a is used. The LNA-anti-miR treated condition shows significantly reduced fluorescence signal compared to the saline treated condition.

International (*pc-pg*): A61K A61K31/7052 A61P A61K31/7088 A61K31/71 A61K31/715 A61K31/712 A61K31/7125 A61K31/713 A61K47/48
A61K48/00 A61P1/16 A61P1/16 A61P1/500 A61P21/00 A61P25/00 A61P29/00 A61P30/00 A61P30/06 A61P31/00 A61P31/04 A61P31/12
A61P31/14 A61P35/00 A61P35/02 A61P37/02 A61P37/06 A61P37/00 A61P7/00 C07H21/00 C07H22/02 C07H22/04 C12N15/09 C12N15/10 C12N15/11 C12N15/113 (AdvancedInvention);
A61K31/7105 A61K31/712 A61P1/16 A61P31/06 A61P31/00 A61P31/14 A61P35/00 A61P9/10 C12N15/11 (AdvancedNon-invention);
A61K31/7042 A61K31/7088 A61K31/71 A61K31/712 A61K31/7125 A61K31/713 A61K48/00 A61P1/00 A61P21/00 A61P25/00 A61P30/00 A61P31/00 A61P35/00 A61P37/00 A61P37/00
A61P9/00 C07H21/00 C12N15/09 C12N15/11 C12N15/113 (CoreInvention);
A61P30/00 A61P31/00 A61P35/00 A61P9/00 (CoreNon-invention);
A61K A61P C07H C12N (SubclassInvention)

International (*pc-1n*): C12N15/11
CPC: C12N15/113 C12N2310/113 C12N2310/321 C12N2310/322 C12N2310/3231 C12N2310/3515 C12N2310/3521 C12N2310/3533
European: C12N15/11 C12N2310/113 M12N310/321 M12N310/3231 M12N310/3515
US: 514/44.00AP 514/44.00R 514/44.00RP 514/44A 514/44R 536/24.1 536/24.100S 536/24.5 536/24.500P

Similar • Translate • Full-text • Status • Citations

Figure 1 consists of a 2x3 grid of micrographs and three histograms below. The micrographs show cell growth for Control-epH4, pro-epH4-21, and anti-epH4-21 under control and FCS conditions. The histograms show the distribution of cell counts for the same conditions.

	Control-epH4	pro-epH4-21	anti-epH4-21
control			
FCS			

Below the micrographs are three histograms showing the distribution of cell counts. The x-axis for all histograms is 'Cell count' ranging from 0 to 250. The y-axis is 'Count' ranging from 0 to 100. The histograms are labeled 'Control-epH4', 'pro-epH4-21', and 'anti-epH4-21'. Each histogram has two bars: a black bar for 'Control' and a white bar for 'FCS'.

- Control-epH4:** The black bar (Control) is at approximately 100, and the white bar (FCS) is at approximately 150.
- pro-epH4-21:** The black bar (Control) is at approximately 100, and the white bar (FCS) is at approximately 150.
- anti-epH4-21:** The black bar (Control) is at approximately 100, and the white bar (FCS) is at approximately 150.

[illegible]

Similar • Translate • Full-text • Status • Citations

[illegible]

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
CN101457224 A	20090617	CN200810204723	20081217	

Title: [EN] MICROMIRS


Abstract: Source: US2009143326A [EN] The present invention relates to very short heavily **modified oligonucleotides** which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.

Classifications: [Classification Explorer](#)

International (ipc 8-9): A61K31/366 A61K31/70 A61K31/7088 A61K31/7105 A61K31/7115 A61K31/712 A61K31/7125 A61K31/713 A61K45/00 A61K45/06 A61K47/48 A61K48/00 A61P3/06 A61P3/14 A61P43/00 C07H21/00 C07H21/02 C07H21/04 C12N C12N15/09 C12N15/11 C12N15/113 C12N5/02 (Advanced/Invention); A61K31/7105 A61K48/00 C12N15/113 (Advanced/Non-invention); C12N15/11 C12N15/113 (Core/Invention)

International (pc 1-7): C12N15/11**CPC:** C12N15/113 A61K31/713 A61K45/06 C12N2310/315 C12N2310/351 C12N2310/3341 C12N15/111 C12N15/1131 C12N2310/113 C12N2310/14 C12N2310/141 C12N2310/32 C12N2310/3231 C12N2320/31**European:** C12N15/113A C12N15/11M M12N310/113 M12N310/14 M12N310/141 M12N310/32 M12N310/3231 M12N320/31**US:** 435/375 435/375S 514/44 514/44.00AP 514/44.00RP 514/44A 514/44R 514/460 514/460S 530/391.7 536/24.1 536/24.5 536/24.500S**Family:** [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2008306327 AA	20090409	AU20080306327	20081003	
AU2008306327 BB	20140515	AU20080306327	20081003	
CA2701547 AA	20100401	CA20082701547	20081003	
CN101821391 A	20100901	CN200880110388	20081003	

Title: [EN] CHEMICALLY **MODIFIED OLIGONUCLEOTIDES**

Abstract: Source: US2006058266A [EN] This invention relates composition and methods for making and using chemically **modified oligonucleotides** agents for inhibiting gene expression.

Classifications: [Classification Explorer](#)

International (ipc 8-9): A61K31/675 A61K31/70 A61K31/7088 A61K31/7105 A61K31/713 A61K47/48 A61K48/00 A61P1/16 A61P1/00 A61P11/06 A61P11/08 A61P13/12 A61P27/02 A61P27/06 A61P27/12 A61P3/06 A61P3/10 A61P31/12 A61P35/00 A61P9/10 C07D401/14 C07D403/06 C07F9/06 C07F9/24 C07H21/04 C07J41/00 C12N15/09 C12N15/11 C12N15/113 C12N15/87 (Advanced/Invention); A61K31/675 A61K31/70 A61K31/7088 A61K31/7105 A61K48/00 A61P1/00 A61P11/00 A61P13/00 A61P27/00 A61P3/00 A61P31/00 A61P35/00 A61P9/00 C07D401/00 C07D403/00 C07F9/00 C07H21/00 C07J41/00 C12N15/09 (Core/Invention)

CPC: C07F9/06 A61K47/48023 A61K47/48046 A61K47/48107 A61K47/48123 C12N15/111 C12N15/87 C12N2310/351 C12N2320/32 C12N2320/51 A61K31/713 C12N2310/3515 C12N2310/14 C12N2310/113 C12N15/113 A61K31/7088**European:** A61K47/48H4 A61K47/48H4F A61K47/48H4Q8 A61K47/48H4R A61K48/00 C12N15/113 C12N15/11M C12N15/87 M12N310/351 M12N320/32 M12N320/51

US: 435/375 514/44 514/44.00RP 514/44A 514/44R 514/81 514/81P 536/23.1 536/23.100S 536/24.5 540/113 540/113S 540/5 540/5P 544/243 544/243S 544/244 544/244S 544/84 544/84S 546/23 546/23S 546/278.4 546/278.400S 548/413 548/415 548/415S 548/468 548/468S

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2005272816 AA	20060223	AU20050272816	20050810	
AU2005272816 BB	20110811	AU20050272816	20050810	

